Ascendiant Capital Markets Lowers Alzamend Neuro (NASDAQ:ALZN) Price Target to $32.00

Alzamend Neuro (NASDAQ:ALZN) had its target price lowered by Ascendiant Capital Markets from $35.00 to $32.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Alzamend Neuro Stock Performance

Alzamend Neuro stock opened at $1.19 on Monday. Alzamend Neuro has a fifty-two week low of $1.06 and a fifty-two week high of $15.06. The firm’s fifty day moving average price is $1.45 and its 200-day moving average price is $2.66.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.